boehringer ingelheim glp-1 π¨ Survodutide, a weekly subcutaneous dual GLP-1/glucagon agonist, posts new top-line Phase 3 results today π SYNCHRONIZE-1: Adults with overweight/obesity randomized to survodutide vs. placebo for 76 weeks βοΈ 16.6% weight loss ( Boehringer Ingelheim's Survodutide Delivers 16.6%
Description
Cardiovasc Diabetol 2023;22(1)
Understanding the Emotional Shift Stopping GLP-1 treatment often feels like ending a partnership with something that made food feel manageable
Dosierung Gemss der Fachinformation
Living Medical eTextbook, Point in Knowlegde
Dose escalation by concentration Look at how dramatically the unit amounts differ between concentrations
These drugs also exhibit additional benefits, such as cardio- and neuroprotection, anti-inflammatory properties, and modulation of reward and food intake behaviors
